NCT04908709 Spectroscopic MRI Guided Proton Therapy in Assessing Metabolic Change in Pediatric Patients With Brain Tumors
| NCT ID | NCT04908709 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Emory University |
| Condition | Malignant Brain Glioma |
| Study Type | INTERVENTIONAL |
| Enrollment | 25 participants |
| Start Date | 2018-12-20 |
| Primary Completion | 2029-10-13 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 25 participants in total. It began in 2018-12-20 with a primary completion date of 2029-10-13.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This trial studies how well spectroscopic magnetic resonance imaging (MRI) guided proton therapy works in assessing metabolic change in pediatric patients with brain tumors. The non-invasive imaging, such as spectroscopic MRI may help to map the differences in tumor metabolism compared to healthy tissue without injection of any contrast agent.
Eligibility Criteria
Inclusion Criteria: * Pathologically diagnosed high-grade glioma (World Health Organization \[WHO\] grade 3-4). Patients with a radiographically diagnosed high-grade glioma may enroll prior to pathologic confirmation, but would be removed from study if pathology did not confirm the diagnosis of high-grade glioma. * Primary tumor located within the supratentorial brain. * Recommended to receive definitive radiation therapy. * Able to receive MRI scans. * Both males and females, and members of all races and ethnic groups are eligible for this trial. Exclusion Criteria: * Patients with pacemakers, non-titanium aneurysm clips, neurostimulators, cochlear implants, non-titanium metal in ocular structures, or other incompatible implants which makes MRI safety an issue are excluded. * Patients that have any significant medical illnesses that in the investigator's opinion cannot be adequately tolerate MRI scan are excluded. * Pathology demonstrated low-grade glioma or other benign or non-invasive brain tumor.
Contact & Investigator
Bree R Eaton, MD
PRINCIPAL INVESTIGATOR
Emory University Hospital/Winship Cancer Institute
Frequently Asked Questions
Who can join the NCT04908709 clinical trial?
This trial is open to participants of all sexes, up to 21 Years, studying Malignant Brain Glioma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04908709 currently recruiting?
Yes, NCT04908709 is actively recruiting participants. Contact the research team at brupper@emory.edu for enrollment information.
Where is the NCT04908709 trial being conducted?
This trial is being conducted at Atlanta, United States, Atlanta, United States, Atlanta, United States.
Who is sponsoring the NCT04908709 clinical trial?
NCT04908709 is sponsored by Emory University. The principal investigator is Bree R Eaton, MD at Emory University Hospital/Winship Cancer Institute. The trial plans to enroll 25 participants.